Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 835 | 91 | 725 |
| Samples | 200 | 36 | 157 |
| Peptides | 156 | 24 | 127 |
Function
HYAL3 · Hyaluronidase 3
This gene encodes a member of the hyaluronidase family. Hyaluronidases are endoglycosidase enzymes that degrade hyaluronan, one of the major glycosaminoglycans of the extracellular matrix. The regulated turnover of hyaluronan plays a critical role in many biological processes including cell proliferation, migration and differentiation. The encoded protein may also play an important role in sperm function. This gene is one of several related genes in a region of chromosome 3p21.3 associated with tumor suppression, and the expression of specific transcript variants may be indicative of tumor status. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene, and some isoforms may lack hyaluronidase activity. This gene overlaps and is on the same strand as N-acetyltransferase 6 (GCN5-related), and some transcripts of each gene share a portion of the first exon. [provided by RefSeq, Jan 2011].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 146 amino-acid changes on canonical ENST00000336307 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in HYAL3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in HYAL3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Rhabdomyosarcoma | 0/33 0% | 5/171 3% |
| Endometrial Carcinoma | 1/42 2% | 10/612 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Colorectal Carcinoma | 9/143 6% | 29/3239 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Melanoma | 2/210 1% | 18/1899 1% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 8/1390 1% |
| Thyroid Gland Carcinoma | 1/45 2% | 12/1592 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 6/810 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Neuroblastoma | 2/87 2% | 3/1331 0% |
| Other Solid Cancers | 1/94 1% | 4/1515 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 6/2534 0% |
| Ovarian Carcinoma | 0/109 0% | 3/998 0% |
| Esophageal Carcinoma | 2/23 9% | 0/769 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
Mutation Distribution
Where HYAL3 is mutated · all tissues, split by cell line vs tissue
How many mutations in HYAL3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 835 mutations in HYAL3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|